Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes

Part of paid clinical trials in Iowa City, Iowa.

Sponsor
Anna Stanhewicz, PhD
Study ID
NCT05917587
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Gestational Diabetes

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 45 Years
Healthy Volunteers
Accepted

Interventions

  • Metformin Hydrochloride — DRUG
    12 weeks: 850mg metformin once daily for first 7 days then twice daily for the remaining 11 weeks.
  • placebo — OTHER
    12 weeks: placebo tablet once daily for the first 7 days then twice daily for the remaining 11 weeks.

Study Details

The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease.

Key Dates

Start date
Sep 11, 2024
Status verified
May 2025
Primary completion
Dec 31, 2027
Completion
Jun 30, 2028

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Active Comparator: metformin
  • Placebo Comparator: placebo

Primary Outcome Measure

blood flow response to acetylcholine [ Time Frame: baseline ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of IowaIowa CityIowa52242
Anna Stanhewicz, PhD
[email protected]
319-467-1732

Find similar trials in Iowa City, IA

By research site
University of Iowa· Iowa City, IA

Related Studies